arrow
G

Gerhard Gründer

central institute of mental health
H指数:49
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression

犬尿氨酸通路谱作为氯胺酮治疗难治性抑郁症反应的标志物

2026-07-010
OAAI
Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6-and 12-Month Naturalistic Follow-Up of a Phase 2b Trial

难治性重度抑郁症中裸盖菇素联合心理治疗的长效疗效:一项2b期试验的6个月和12个月自然随访

2026-05-010
PRE
High Clozapine Serum Levels Do Not Improve Response: An Observational Study in Patients with Schizophrenia Treated with Clozapine in a Naturalistic Setting

高血清氯氮平水平并未改善疗效:一项在自然环境中接受氯氮平治疗的精神分裂症患者的观察性研究

2026-05-011
PRE
Disturbed Functional Connectivity Between Anterior Default Mode and Sensory Processing Regions Is Linked to Peripheral Inflammatory Markers and Psychopathology in Schizophrenia

精神分裂症患者中,前默认模式网络与感觉处理区域之间功能连接的紊乱与外周炎症标志物及精神病症状相关。

2025-04-230
PRE
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: Focus on antipsychotics

通过治疗药物监测,分子脑成像和药物遗传学测试优化精神病学中的药物治疗: 专注于抗精神病药

2024-09-015
PRE
Identifying differential predictors for treatment response to amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia: Results of the COMBINE-study
2024-08-010
OAAI
Functional connectivity signatures of NMDAR dysfunction in schizophrenia-integrating findings from imaging genetics and pharmaco-fMRI
2023-02-1613
OAAI
Systematic review and meta-analysis on the therapeutic reference range for escitalopram: Blood concentrations, clinical effects and serotonin transporter occupancy
2022-10-179
OAAI